BreastSurgANZ members recommendations for adjuvant systemic treatment and patient compliance in Australian breast cancer patients

2021 ◽  
Author(s):  
Arlene Chan ◽  
Nicola O'Neil ◽  
Chris Lomma ◽  
HuiJun Chih ◽  
Peter Willsher
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Patient Compliance ◽  
Systemic Treatment ◽  
Breast Cancer Patients ◽  
Adjuvant Systemic Treatment

Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial

2021 ◽  
Author(s):  
J.M.N. Lopes Cardozo ◽  
D. Byng ◽  
C.A. Drukker ◽  
M.K. Schmidt ◽  
M.A. Binuya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Adjuvant Systemic Treatment ◽  
Her2 Breast Cancer

Timing of re-excision surgery (S2) for positive margins (PM) and initiation of adjuvant systemic treatment (aRx) in early breast cancer patients (BC pts).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e11065-e11065
Author(s):  
L. De Mattos-Arruda ◽  
I. Rubio ◽  
L. Garcia-Aceituno ◽  
J. Cortes ◽  
G. Sanchez-Olle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Systemic Treatment ◽  
Breast Cancer Patients ◽  
Positive Margins ◽  
Adjuvant Systemic Treatment

Abstract P6-08-17: The 70-gene signature affects adjuvant systemic treatment decisions in breast cancer patients: A population-based, observational study

2015 ◽  
Author(s):  
Anne Kuijer ◽  
Annelotte CM van Bommel ◽  
Margriet van der Heiden- van der Loo ◽  
Carolien A Drukker ◽  
Thijs van Dalen
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Gene Signature ◽  
Treatment Decisions ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Adjuvant Systemic Treatment

Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns

2014 ◽  
Vol 13 (11) ◽  
pp. 1443-1467 ◽  
Author(s):  
Omar Abdel-Rahman ◽  
Hesham ElHalawani
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Breast Cancer Patients ◽  
Safety Concerns ◽  
Adjuvant Systemic Treatment

Abstract PS11-01: Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial

2021 ◽  
Author(s):  
Josephine MN Lopes Cardozo ◽  
Danalyn Byng ◽  
Caroline A Drukker ◽  
Marjanka K Schmidt ◽  
Laura J van 't Veer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Breast Cancer Patients ◽  
Adjuvant Systemic Treatment

scholarly journals Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study

BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e017842 ◽  
Author(s):  
Gwen MHE Dackus ◽  
Natalie D ter Hoeve ◽  
Mark Opdam ◽  
Willem Vreuls ◽  
Zsuzsanna Varga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
The Netherlands ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Systemic Treatment ◽  
Young Patients ◽  
Breast Cancer Patients ◽  
Adjuvant Systemic Treatment ◽  
Netherlands Cancer Registry ◽  
Young Breast Cancer

IntroductionCurrently used tools for breast cancer prognostication and prediction may not adequately reflect a young patient’s prognosis or likely treatment benefit because they were not adequately validated in young patients. Since breast cancers diagnosed at a young age are considered prognostically unfavourable, many treatment guidelines recommend adjuvant systemic treatment for all young patients. Patients cured by locoregional treatment alone are, therefore, overtreated. Lack of prognosticators for young breast cancer patients represents an unmet medical need and has led to the initiation of the PAtients with bReAst cancer DIaGnosed preMenopausally (PARADIGM) initiative. Our aim is to reduce overtreatment of women diagnosed with breast cancer aged≤40 years.Methods and analysisAll young, adjuvant systemic treatment naive breast cancer patients, who had no prior malignancy and were diagnosed between 1989 and 2000, were identified using the population based Netherlands Cancer Registry (n=3525). Archival tumour tissues were retrieved through linkage with the Dutch nationwide pathology registry. Tissue slides will be digitalised and placed on an online image database platform for clinicopathological revision by an international team of breast pathologists. Immunohistochemical subtype will be assessed using tissue microarrays. Tumour RNA will be isolated and subjected to next-generation sequencing. Differences in gene expression found between patients with a favourable and those with a less favourable prognosis will be used to establish a prognostic classifier, using the triple negative patients as proof of principle.Ethics and disseminationObservational data from the Netherlands Cancer Registry and left over archival patient material are used. Therefore, the Dutch law on Research Involving Human Subjects Act (WMO) is not applicable. The PARADIGM study received a ‘non-WMO’ declaration from the Medical Ethics Committee of the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, waiving individual patient consent. All data and material used are stored in a coded way. Study results will be presented at international (breast cancer) conferences and published in peer-reviewed, open-access journals.

The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients

2014 ◽  
Vol 143 (3) ◽  
pp. 469-476 ◽  
Author(s):  
L. M. van Roozendaal ◽  
R. J. Schipper ◽  
K. K. B. T. Van de Vijver ◽  
C. M. Haekens ◽  
M. B. I. Lobbes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Lymph Node Status ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Adjuvant Systemic Treatment ◽  
Node Negative Breast Cancer ◽  
The Impact

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

2007 ◽  
Vol 112 (1) ◽  
pp. 203-213 ◽  
Author(s):  
Brigitte Mlineritsch ◽  
Christoph Tausch ◽  
Christian Singer ◽  
Gero Luschin-Ebengreuth ◽  
Raimund Jakesz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Cancer Patients ◽  
Phase Ii Trial ◽  
Systemic Treatment ◽  
Study Group ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive ◽  
Cancer Study Group ◽  
Post Menopausal

Preoperative systemic treatment in breast cancer patients. Does the site of response matter?

2020 ◽  
Vol 138 ◽  
pp. S91-S92
Author(s):  
A. Esgueva ◽  
C. Siso ◽  
I. Miranda ◽  
C. Sobrido ◽  
M. Espinosa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document